Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
169.71-1.92 (-1.12%)
At close: 4:00 PM EDT
People also watch:
BIIBGILDCELGMRKBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open172.22
Prev Close171.63
Bid170.00 x 100
Ask171.78 x 200
Day's Range169.05 - 172.22
52wk Range135.64 - 176.85
1y Target EstN/A
Market Cap127B
P/E Ratio (ttm)17.37
Beta1.34
Volume2,961,818
Avg Vol (3m)2,840,878
Dividend & Yield4.00 (2.33%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Investopedia10 hours ago

    Amgen Reports Positive Results for Trial (AMGN)

    Positive top-line data from an ongoing high-resolution imaging trial reinstates a promising outlook for treating cardiovascular disease with Repatha.

  • PR Newswire11 hours ago

    Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study

    THOUSAND OAKS, Calif., Sept. 28, 2016 /PRNewswire/ -- Amgen (AMGN) today announced positive top-line results for erenumab (AMG 334) from A Phase 3, RandomIzed, double-blind, placebo-controlled Study to Evaluate the efficacy and safety of erenumab in migraine prevention (ARISE). Erenumab is specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor, which is believed to have a critical role in mediating the incapacitating pain of migraine. "People with episodic migraine lose a substantial part of their lives to migraine, and many face intolerable pain and physical impairment, frequently accompanied by a significant disruption of their daily activities.

  • Investopedia15 hours ago

    3 Nasdaq-100 Stocks Ready to Play Catch-Up

    These Nasdaq-100 components show stronger buying interest than price gains, predicting the price will play catch up in coming months.